Organizational Unit:
Undergraduate Research Opportunities Program

Research Organization Registry ID
Description
Previous Names
Parent Organization
Parent Organization
Organizational Unit
Includes Organization(s)

Publication Search Results

Now showing 1 - 2 of 2
  • Item
    Modeling Aortic Valvular Leaflet Thrombosis Risk Following Transcatheter Aortic Valve Replacement
    (Georgia Institute of Technology, 2022-05) Venkatesh, Aniket
    Calcific aortic stenosis (AS) is the thickening of the aortic valve leaflets in the heart due to calcium buildup. Currently, the most widespread treatment option is transcatheter aortic valve replacement (TAVR), a minimally invasive interventional procedure where a prosthetic valve is delivered to replace the diseased one. Despite TAVR’s effectiveness in treating AS, there have been reported instances of leaflet thrombosis (LT), which is characterized by the formation of blood clots around a leaflet of a prosthetic valve. Therefore, this study aimed to predict the risk of LT following different, controllable prosthetic valve deployment orientations through computational simulations. Normalized circulation, a quantity found to be inversely related to expected thrombus volume, was calculated following each deployment orientation and it was determined that different prosthetic valve commissural alignments may lead to higher NCs and lower risk of LT, but neither different stent rotational orientations nor different stent expansion volumes had a significant effect on NCs, and therefore risk of LT development. Additionally assessment of blood flow profiles post-TAVR deployments demonstrated that the maximum blood speed reached and the maximum pressure drop through the aortic valve were both decreased towards their respective healthy ranges.
  • Item
    The Selective Benefits of Acute Dosing with Dopamine Receptor Agonists on the Visual Function, Cognitive Function, and Blood Glucose Levels in a Rat Model of Type I Diabetes
    (Georgia Institute of Technology, 2021-05) Cardelle, Lidia
    Purpose: Previous studies have demonstrated that dopamine D1 and D4 receptor (D1R, D4R) agonists selectively improve spatial frequency and contrast sensitivity thresholds, respectively, in healthy and diabetic mice (Jackson et al., 2012; Aung et al., 2014). The purpose of this experiment was to investigate the selective benefits of three dopamine receptor agonists (D1R, D2R, D4R) on visual function, cognitive function, and blood glucose in a rat model of Type I diabetes with progression of diabetes. Methods: Streptozotocin (STZ) was used to induce hyperglycemia in 2-month-old male Long–Evans rats (n=17). Outcome measures were acquired before and 30 minutes after an intraperitoneal injection of a single dose of a dopamine receptor agonist. Each agonist was injected 2-3 days apart. After 8, 16 and 20 weeks post-STZ, optomotor response (OMR) assessments were conducted. After 10 weeks post-STZ, blood glucose and Y-maze performance were measured on a subset of animals (n=4 diabetics; 6 controls). The spatial frequency, contrast sensitivity, Y-maze performance, and blood glucose for the diabetic rats and control rats post injection were compared to the baseline values to determine the effect of the acute dosing of each dopamine receptor agonist. Results: At the 8, 16, and 20 week timepoints, spatial frequency and contrast sensitivity thresholds were impaired in diabetic animals compared to controls (p<0.0001). At 8 weeks post-STZ, D1R agonist selectively restored spatial frequency thresholds for diabetic rats (p<0.0001), but did not alter thresholds in control rats. At 8 weeks post-STZ, the D4R agonist selectively restored contrast sensitivity thresholds for diabetic rats (p<0.0001) but did not alter thresholds for control rats. The improvements that we observed at 8 weeks in the diabetic animals with the D1R and D4R agonists were no longer observed at 16 or 20 weeks. The D2R agonist did not demonstrate any effects at any timepoint. There was no significant differences in Y-maze and blood glucose values with agonist treatment. Conclusions: Based on these findings, acute dosing of dopamine receptor agonists selectively benefits visual acuity (D1R) and contrast sensitivity (D4R) at early stages of diabetic retinopathy. Thus, dopamine receptor agonists may provide protective treatment options for early stage visual deficits characteristic of Type I diabetes.